Board of Directors

Declan Doogan, M.D.

Image of Declan Doogan, M.D.

Chairman and Director

Dr. Doogan is a seasoned drug development executive and life sciences investor with more than 30 years experience in the global pharmaceutical industry. He joined Pfizer in 1982, where he held a number of senior positions in R&D in the USA, UK and Japan. Dr. Doogan was the clinical development head for what was to become ZOLOFT, an important antidepressant and one of the top selling products in the world. He retired from Pfizer in 2007 as the Senior VP Head of World Drug Development. Subsequently Dr. Doogan was Head of R&D at Amarin where, along with the CEO, he raised $100m to fund the reorganization and portfolio realignment leading to completion of a Phase III program and NDA approval for Vascepa (icosapent ethyl) for elevated triglycerides. During his career Dr. Doogan has engaged in activities to promote excellence in pharmaceutical medicine and sits on the Boards of several biotechnology companies.

Eric Aguiar, M.D.

Image of Eric Aguiar, M.D.


Dr. Aguiar is a partner at Aisling Capital and previously was a partner at Thomas, McNerney and Partners, a $600 million health care focused venture capital and growth equity fund, from 2007-2015. Eric was a Managing Director of HealthCare Ventures, a health care venture capital fund, from 2001-2007. Eric currently sits on the board of Invitae Corporation, a NYSE listed company.

His prior board seats have included Amarin, Oriel Therapeutics, Inc. (acquired by Novartis AG), Virdante Pharmaceuticals, Inc. (acquired by Momenta Pharmaceuticals), CardioKine, Inc. (acquired by Cornerstone Therapeutics), SkinMedica, Inc (acquired by Allergan), Vaxinate, Inc., Metaphore, and 3-D Pharmaceuticals (acquired by Johnson & Johnson). Eric was CEO of Genovo, Inc. (acquired by Targeted Genetics), a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. (acquired by Watson Pharmaceuticals). Eric was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997. He is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. Eric received his Medical Degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. Eric was also a Luce Fellow and is a Chartered Financial Analyst.

Gregory H. Bailey, M.D.

Image of Gregory H. Bailey, M.D.


Dr. Bailey has spent the last fifteen years as an entrepreneur, executive and financier in the health care sector. He is currently Chairman of the Board at Portage Biotech Inc. and has served on the Board of Directors for 16 public companies. He is a former director and financier of Medivation Inc. (MDVN: NASDAQ) and co-founder of Ascent Healthcare Solutions, VirnetX Inc internet security (VHC: AMEX) and Duramedic Inc., a medical products company. Prior posts within the investment and financial services sector included serving as Managing Director of Gilford Securities Inc., Managing Director of Knightsford Bank Corp, Senior Managing Director positions at Viscogliosi Brothers and the LXV Prosperity Fund, founder and General Manager of the ABN Private Equity Fund, co-foundeer of EuroAmerican Mercantile Bancorp, and co-founder and CEO of V-Fund Investments, Ltd. Dr. Bailey received his Medical Degree from the University of Ontario before practicing for ten years as an emergency room Physician.

Albert Cha

Image of Albert Cha


Dr Cha is a Managing Partner at Vivo Capital and invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), Carbylan Therapeutics (NASDAQ: CBYL), and several private companies.

He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.

John W. Childs

Image of John W. Childs


Mr. John W. Childs serves as the Chairman and Partner of J.W. Childs Associates, L.P., a private equity firm. He co-founded J.W. Childs Associates in 1995. Prior to founding J.W. Childs Associates, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company from 1991 to 1995. In this capacity, he had broad responsibilities for originating, analyzing, negotiating and managing leveraged buyout transactions for the THL funds.

For seventeen years prior to joining THL, Mr. Childs was with the Prudential Insurance Company of America where he held various executive positions in the investment area, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. He is currently Chairman of Sunny Delight and a director of Kosta Browne, Esselte, Mattress Firm, WS Packaging and SIMCOM. Prior to its sale, he was Chairman of the Board of CHG Healthcare Services. Mr. Childs has a B.A. from Yale University and a M.B.A. from Columbia University.

Vlad Coric, M.D.

Image of Vlad Coric, M.D.

Chief Executive Officer and Director

Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma.

He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.